Date: Monday, June 20, 2016
Session Title: Parkinsonism, MSA, PSP (secondary and parkinsonism-plus)
Session Time: 12:30pm-2:00pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate the differences in striatal subregional dopamine transporter loss in Parkinson’s disease (PD) and supranuclear palsy (PSP) and the diagnostic value of [18F]PR04.MZ PET in differentiating both diseases.
Background: PD and PSP are neurodegenerative parkinsonism characterized by loss of striatal dopaminergic activity secondary to neuronal loss. They are associated with different patterns of involvement, especially in the first years of evolution of motor symptoms.
Methods: Seven patients with PSP (mean age 72±2.1 and 2.4±0.5 years disease of evolution) and 7 patient with IPD (mean age 71.3±2.1 and 2.4±0.3 years disease of evolution) matched by age and time of evolution of the disease underwent a static PET scan (Siemens mCT) with the radioligand selective for Dopamine transporter (DAT) [18F]PR04.MZ., 75 min after bolus injection of 231 ± 51 MBq (mean ± SD) PET scans were co-registrated to CT images and normalized to a standardized brain template. Binding potentials (BPnd) in different brain regions were calculated as region/cerebellum-1. Data Analysis Results are expressed with average and ranges. × plus or minus standard deviation.
Results: Loss of dopaminergic activity was evident in all the striatal regions in both groups as compared to healthy subjects. Lower dopaminergic activity was observed in all striatal regions in PSP as compared with PD patients. Statistical significant difference was present less affected side in total and posterior putamen.
|Region||Side||PD group||PSP group||P|
|Whole striatum||More affected||4.6±2.4||2.7±3.5||NS|
|Caudate Total||More affected||10.4±4.5||7.6±2.3||NS|
|Putamen Total||More affected||7.7±4.0||4.7±3.4||NS|
|Putamen anterior||More affected||10.2±5.6||5.9±3.4||NS|
|Putamen posterior||More affected||4.6±2.4||2.7±3.5||NS|
Conclusions: A more prominent and earlier loss of presynaptic dopaminergic activity was evident in PSP as compared to PD patients. Larger studies are needed to evaluate the usefulness of this finding in the differential diagnosis of PSP.
To cite this abstract in AMA style:P. Chana-Cuevas, C. Juri, V. Kramer, R. Pruzzo, P. Riss, A. Amaral, F. Rösch, H. Amaral. Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/quantification-of-striatal-dopamine-transporters-with-18fpr04-mz-in-patients-with-progressive-supranuclear-palsy-and-parkinsons-disease/. Accessed December 6, 2023.
« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/quantification-of-striatal-dopamine-transporters-with-18fpr04-mz-in-patients-with-progressive-supranuclear-palsy-and-parkinsons-disease/